People News: Abbott Labs and Lux Biosciences

Abbott Laboratories executive vice president of pharmaceuticals Olivier Bohuon is leaving the company to become CEO at Pierre Fabre Group, a French pharmaceutical company, beginning September 1. Richard Gonzalez, a former president and COO at Abbott, will lead Abbott's pharmaceutical division on an interim basis, according to an Associated Press report. Abbott's pharmaceutical division is responsible for the lion's share of the company's total revenue, due mostly to Humira, a blockbuster injection indicated for rheumatoid arthritis, Crohn's disease and other inflammatory conditions. The pharmaceuticals division pulled in $4.1 billion in sales for the first quarter of 2010, according to the AP.

Lux Biosciences hired Dean Mitchell as president and CEO. Mitchell had been president and CEO of Alpharma before that company was acquired by King in 2008.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.